Comparative Pharmacology
Head-to-head clinical analysis: EC NAPROSYN versus IBUPROFEN AND DIPHENHYDRAMINE CITRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EC NAPROSYN versus IBUPROFEN AND DIPHENHYDRAMINE CITRATE.
EC-NAPROSYN vs IBUPROFEN AND DIPHENHYDRAMINE CITRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and thereby decreasing pain, fever, and inflammation. Diphenhydramine citrate is an antihistamine that antagonizes histamine H1 receptors, producing sedative and anticholinergic effects.
500-1000 mg orally twice daily; maximum 1500 mg/day.
Ibuprofen 200 mg + Diphenhydramine citrate 38 mg (equivalent to diphenhydramine HCl 25 mg) orally every 4-6 hours as needed, not to exceed Ibuprofen 1200 mg/day or Diphenhydramine citrate 152 mg/day.
None Documented
None Documented
Terminal elimination half-life 12-17 hours (mean 14 hours); prolonged in elderly and renal impairment
Ibuprofen: terminal elimination half-life approximately 1.8-2.5 hours in adults; prolonged in elderly and patients with hepatic impairment. Diphenhydramine: terminal elimination half-life ranges from 4 to 10 hours (mean 7 hours); may be prolonged in elderly and hepatic impairment.
Renal (95%) as unchanged drug (10%) and conjugated metabolites (60%) and other metabolites (25%); biliary/fecal (5%)
Ibuprofen: renal elimination of metabolites (approximately 90%) and unchanged drug (approximately 10%); fecal elimination <5%. Diphenhydramine: primarily renal elimination (approximately 60-70% as metabolites, 1-2% unchanged); fecal elimination approximately 10-15%.
Category C
Category D/X
NSAID
NSAID